Industry
Combination therapy emerges as option when weight-loss injections fall short
GLP-1 drugs have surged in use for obesity and weight loss, but research suggests up to 20 percent of patients may not see enough benefit. A review paper cited by Medical News Today said combining a naltrexone-bupropion product, Contrave, with GLP-1 therapy could be an alternative. Researchers said the drugs target different pathways, including satiety and food cravings, and clinicians said there is no single treatment that works for everyone.
